May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Use of Mitomycin C in the Treatment of Conjuntival Primary Acquired Melanosis With Atypia
Author Affiliations & Notes
  • A. Nava-Castaneda
    Oculoplastics, Conde de Valenciana, Mexico City, Mexico
  • J. Tovilla-Canales.
    Oculoplastics, Conde de Valenciana, Mexico City, Mexico
  • R.I. Flores
    Oculoplastics, Conde de Valenciana, Mexico City, Mexico
  • J. Tovilla-y-Pomar
    Oculoplastics, Conde de Valenciana, Mexico City, Mexico
  • O. Schneider
    Oculoplastics, Conde de Valenciana, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  A. Nava-Castaneda, None; J. Tovilla-Canales., None; R.I. Flores, None; J. Tovilla-y-Pomar, None; O. Schneider, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3795. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Nava-Castaneda, J. Tovilla-Canales., R.I. Flores, J. Tovilla-y-Pomar, O. Schneider; Use of Mitomycin C in the Treatment of Conjuntival Primary Acquired Melanosis With Atypia . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3795.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Primary acquired melanosis (PAM)is a flat, brown, superficial discoloration caused by intraepithelial melanocytes of the conjunctiva. Histologically, PAM can be differentiated in without atypia which is a benign disease, or with atypia that has shown to have a high risk of melanoma, and needs to be eliminated. Treatment for PAM with atypia includes resection and cryotherapy. Unfortunately, these treatments have severe limitations and complications. Recently,use of topical mitomycin C (MMC) in the treatment of PAM with atypia has shown promising results in some series. However, long term follow-up in these sereies are lacking. Purpose: To evaluate a long term follow-up of patients with PAM with atypia treated with MMC. Methods: Two hispanic patients with histopathological diagnosis of PAM with atypia were treated with MMC (0.02%) four times a day for 15 days. After a resting period of 15 days without medication, a second treatment with MMC (0.02%) qid for another 15 days was given. Patients have been followed-up with a complete ophthalmological evaluation and conjuntival biopsy for the last 5 years. Results: Pigmentation of the conjunctiva substantially improved after the first phase of the treatment. Biopsies performed annually since then, have revealed a decreases presence of melanophagus, decreased mitosis, and no presence of atypical melanocytes. No adverse reactions other than mild keratoconjunctivitis that presented during the treatment phase ocurred. Conclusions: MMC at 0.02% showed to be an effective treatment for PAM with atypia at a 5 years follow-up in our series.

Keywords: conjunctiva • tumors • oncology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×